Effects of Arylsulfatase B and Pembrolizumab in Combination on Progression of Metastatic Melanoma in the B16F10 Syngeneic Mouse Model

This study demonstrates that combining Arylsulfatase B (ARSB), which promotes melanoma cell apoptosis via COP1 upregulation, with Pembrolizumab, which targets cytotoxic lymphocytes, yields synergistic effects that reduce tumor invasiveness and improve survival outcomes in metastatic B16F10 melanoma.

The Gist

The Big Picture: A Two-Pronged Attack on Melanoma

Imagine the body is a fortress, and Melanoma (a dangerous skin cancer) is a group of invaders trying to take over. Usually, the body's security guards (the immune system) try to stop them, but the cancer is tricky. It wears a "disguise" that tells the security guards, "Hey, I'm friendly, don't shoot!"

This paper tests a new strategy: combining two different weapons to defeat the cancer.

1. Weapon A (Pembrolizumab): This is a well-known drug that acts like a "disguise remover." It strips away the cancer's camouflage so the security guards can see and attack it.
2. Weapon B (Arylsulfatase B or ARSB): This is a new, experimental enzyme. Think of it as a "structural engineer" that fixes the cancer's internal wiring and removes its escape routes.

The researchers wanted to see if using both weapons together works better than using just one.

---

The Cast of Characters

• The Cancer (B16F10): A very aggressive type of melanoma that loves to travel through the bloodstream and set up camp in the lungs.
• The Security Guards (Immune Cells): Specifically, the "Special Forces" (T-cells) and the "Rapid Response Team" (Neutrophils/PMNs).
• The Disguise (PD-L1): A flag the cancer waves to tell the Special Forces, "Stop! I'm a friend." Pembrolizumab rips this flag off.
• The Sticky Glue (Chondroitin 4-Sulfate): A sticky substance on the cancer's surface that helps it hide and move around. When the enzyme ARSB is missing, this glue builds up, making the cancer stronger and more slippery.
• The Structural Engineer (ARSB): The missing piece. When you add it back, it cleans up the sticky glue, making the cancer weaker and easier to kill.

---

What Happened in the Experiments?

The scientists ran tests on mice with lung metastases (cancer that has spread to the lungs) and in petri dishes with human cancer cells. Here is what they found:

1. The "Disguise" vs. The "Engineer"

• Pembrolizumab alone: It successfully removed the cancer's disguise, allowing the Special Forces to attack. It worked, but the cancer still had some tricks up its sleeve.
• ARSB alone: It cleaned up the sticky glue on the cancer. This made the cancer cells "self-destruct" (a process called apoptosis) and stopped them from moving around as easily.
• The Combination (The Synergy): When they used both, the results were explosive. The cancer didn't just get attacked; it fell apart from the inside and was swarmed by the immune system from the outside.
  • Analogy: Imagine a castle. Pembrolizumab opens the gates so the army can get in. ARSB removes the walls and the moat so the castle can't defend itself. Together, the castle collapses instantly.

2. Cutting the Escape Routes (MMPs)

Cancer cells need to break through walls (tissue) to spread to new organs. They use tools called MMPs (Matrix Metalloproteinases) to cut holes in the walls.

• The Finding: ARSB acts like a tool-belt thief. It steals the MMPs from the cancer cells, leaving them with no way to break out and spread. Pembrolizumab didn't do this on its own, but the combination stopped the spread more effectively than either drug alone.

3. The "Smoke Signal" (Cytokines)

Cancer cells often send out "smoke signals" (chemical messages) to call for help or to confuse the immune system.

• The Finding: The combination treatment changed the smoke signals. It reduced the "panic" signals that cause inflammation and increased the "help" signals that recruit more immune cells to the fight.

4. The Neutrophil Twist (The "Rapid Response Team")

This was a surprising discovery. The researchers found that ARSB changes how the cancer interacts with Neutrophils (a type of white blood cell).

• Normally, cancer might trap neutrophils. But with ARSB treatment, the cancer actually started releasing more of a chemical called IL-8.
• Analogy: It's like the cancer accidentally rang the fire alarm louder. This attracted more "firefighters" (neutrophils) to the scene. When these firefighters arrived, they helped the Special Forces (T-cells) kill the cancer even faster.

---

The Bottom Line

The study suggests that Pembrolizumab (the immune booster) and ARSB (the structural fixer) work in two completely different ways, but they complement each other perfectly.

• Pembrolizumab wakes up the immune system.
• ARSB weakens the cancer's defenses and makes it easier for the immune system to finish the job.

Why does this matter?
Melanoma is a tough enemy. Using just one weapon often isn't enough because the cancer finds a way to adapt. By attacking it from two different angles—fixing its internal wiring and waking up the immune system—the researchers hope to create a treatment that is much more effective, potentially saving lives and preventing the cancer from spreading to the lungs and other organs.

In short: It's not just about shooting the enemy; it's about taking away their shield, breaking their legs, and then calling in the heavy artillery. This paper shows that doing all three at once is a winning strategy.

Technical Summary

1. Problem Statement

Metastatic malignant melanoma remains a devastating disease with significant mortality. While immune checkpoint inhibitors (ICIs) like Pembrolizumab (an anti-PD-1 antibody) have improved outcomes, resistance and incomplete responses remain major challenges.

• The Biological Gap: The enzyme Arylsulfatase B (ARSB) removes 4-sulfate groups from chondroitin 4-sulfate (C4S). A decline in ARSB activity leads to the accumulation of highly sulfated C4S, which acts as an oncofetal antigen and tumor promoter.
• The Hypothesis: The authors hypothesized that combining recombinant human ARSB (rhARSB), which targets tumor cell signaling directly, with Pembrolizumab, which targets infiltrating immune cells, would yield synergistic therapeutic effects. Specifically, they anticipated that rhARSB would enhance Pembrolizumab efficacy by reducing PD-L1 expression and modulating the tumor microenvironment (TME).

2. Methodology

The study utilized a multi-modal approach combining in vivo murine models and in vitro human cell cultures.

• In Vivo Model (Syngeneic Mouse):

  • Subjects: 32 male C57BL/6J mice (10.5 weeks old).
  • Induction: Tail vein injection of 250,000 B16F10 mouse melanoma cells to induce pulmonary metastases.
  • Treatment Groups (Days 2, 7, 12):
    1. Control: Normal saline (IV).
    2. rhARSB: 0.2 mg/kg (IV).
    3. Pembrolizumab: 5 mg/kg (Intraperitoneal).
    4. Combination: rhARSB + Pembrolizumab.
  • Endpoints: Lung metastasis quantification, survival, and tissue analysis (lung, liver, blood) on Day 14.

• In Vitro Models:

  • Cell Lines: A375 human melanoma cells and normal human melanocytes.
  • Interventions: Treatment with rhARSB, Pembrolizumab, siRNA (to silence ARSB or IL-8), and co-culture with Peripheral Blood Mononuclear Cells (PBMCs) and Polymorphonuclear leukocytes (PMNs).
  • Assays:
    • Apoptosis: Cleaved caspase-3 ELISA, BCL2/COP1 mRNA expression.
    • Invasiveness: MMP2/MMP9 activity and mRNA expression; cell migration assays.
    • Cytokine Profiling: qRT-PCR and ELISA for cytokines (IL-6, IL-8, TNF-α, MCP1, etc.) and chemokines.
    • Immune Interaction: PMN migration assays using transwells; co-culture with activated PBMCs.

3. Key Contributions

This study provides novel mechanistic insights into how enzymatic modulation of the extracellular matrix (via ARSB) can synergize with immunotherapy:

1. Dual Mechanism of Apoptosis: Demonstrated that rhARSB and Pembrolizumab induce apoptosis through distinct but complementary pathways.
2. C4S as a Therapeutic Target: Validated that restoring ARSB activity reverses the pro-tumorigenic signaling caused by C4S accumulation (specifically the SHP2 binding pathway).
3. Immune Modulation: Revealed that rhARSB alters the cytokine landscape (specifically IL-8 and MCP1) to facilitate immune cell infiltration and activity, potentially overcoming ICI resistance.
4. Synergy: Provided evidence that the combination therapy is superior to monotherapies in reducing metastasis, invasiveness, and pro-survival signaling.

4. Key Results

A. In Vivo Efficacy (B16F10 Mouse Model)

• Metastasis Reduction: All treatment groups showed fewer pulmonary metastases than controls. The rhARSB group had the fewest tumors, but the combination group also showed significant reduction compared to controls.
• Apoptosis Synergy: The combination of rhARSB and Pembrolizumab produced the greatest increase in cleaved caspase-3 (p=1.2x10⁻⁷) compared to either agent alone.
• Molecular Pathways:
  • COP1 (E3 Ubiquitin Ligase): Expression increased significantly with rhARSB but was unaffected by Pembrolizumab.
  • BCL2 (Anti-apoptotic): Both agents reduced BCL2, but the combination caused the most profound decline (p=3.5x10⁻⁶).
  • Correlation: Strong inverse correlation between BCL2 and cleaved caspase-3 (r = -0.97).

B. Mechanisms of Action

• Matrix Metalloproteinases (MMPs):
  • rhARSB significantly reduced MMP2 and MMP9 expression (critical for metastasis).
  • Pembrolizumab had no effect on MMPs alone.
  • Synergy: The combination resulted in the greatest decline in circulating MMP2 (~58% reduction).
• Cytokine/Chemokine Modulation:
  • Increases: MCP1 and IL-10 were elevated by the combination (enhancing immune recruitment).
  • Decreases: KC (mouse IL-8 analog), IL-6, bFGF, VEGF, and EGF were reduced.
  • TNF-α: Pembrolizumab increased TNF-α, while rhARSB decreased it; the combination resulted in an overall decline.
• PMN and IL-8 Interaction:
  • rhARSB treatment increased IL-8 secretion into the media, which attracted PMNs.
  • Silencing ARSB reduced PMN invasion.
  • Crucial Finding: The pro-apoptotic effect of Pembrolizumab + activated PBMCs was reduced when IL-8 was silenced, indicating IL-8 is a necessary mediator for immune-mediated apoptosis in this context.

C. In Vitro Validation (A375 Cells)

• Apoptosis: The combination of rhARSB + Pembrolizumab + Activated PBMCs resulted in the highest cleaved caspase-3 levels (p=1.9x10⁻¹³).
• Granzyme B: A synergistic increase in Granzyme B was observed with the triple combination, confirming T-cell/immune cell involvement.
• Migration: rhARSB reduced A375 cell migration; silencing ARSB increased it. Pembrolizumab alone did not affect migration.

5. Significance and Conclusion

• Clinical Potential: The study suggests that rhARSB acts as a potent tumor suppressor by directly targeting melanoma cell signaling (via COP1/BCL2) and indirectly modulating the TME (via MMPs and cytokines).
• Synergistic Strategy: Combining rhARSB with PD-1 inhibitors like Pembrolizumab offers a multi-pronged attack:
  1. Direct Tumor Killing: rhARSB induces apoptosis via COP1 upregulation.
  2. Immune Activation: Pembrolizumab reactivates T-cells, while rhARSB facilitates this by reducing immunosuppressive factors (like high C4S binding) and increasing chemokines (MCP1) and immune cell access (via IL-8/PMN dynamics).
• Novel Mechanism: The paper highlights a previously underappreciated role of ARSB in regulating the binding of IL-8 to C4S, which dictates neutrophil (PMN) migration and subsequent immune-mediated tumor cell death.
• Future Directions: While the combination did not show a statistically superior survival advantage over rhARSB alone in the specific 14-day mouse model (where rhARSB alone was highly effective), the molecular data (apoptosis, MMP reduction, cytokine shifts) strongly supports the clinical rationale for testing combined dosing regimens to prevent resistance and improve long-term outcomes in metastatic melanoma.

Note: As this is a preprint, the findings have not yet undergone peer review, and the authors explicitly state the results should not yet guide clinical practice.